CHDI 00484077

Cat. No. 7879 提交评论说明书 / 分析证书（CoA） / 化学品安全技术说明书（SDS）

Pricing	Availability		Qty

说明： Potent and selective HDAC class IIa inhibitor

化学名： N-((R)-1-((S)-2-Methylpyrrolidin-1-yl)propan-2-yl)-4-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide

纯度： ≥98% (HPLC)

文献 (4)

生物活性技术数据溶解性计算器说明书参考文献

生物活性 for CHDI 00484077

CHDI 00484077 is a potent and selective class IIa histone deacetylase HDAC inhibitor (IC₅₀ values = 10-30 nM in vivo, 0.01 nM and 0.04 nM in HEK293 and Jurkat cells, respectively). Exhibits 150-fold selectivity for class IIa over class I/IIb HDACs in cells. Orally bioavailable and CNS penetrant.

许可信息

Sold under license from CHDI Foundation

技术数据 for CHDI 00484077

分子量	382.39
公式	C₁₈H₂₁F₃N₄O₂
储存	Store at -20°C
纯度	≥98% (HPLC)
CAS Number	3025894-92-9
PubChem ID	162675553
InChI Key	DBWSFWPXCPNWRZ-NEPJUHHUSA-N
Smiles	O=C(C1=CC=C(C=C1)C2=NOC(C(F)(F)F)=N2)N[C@@H](CN3[C@H](CCC3)C)C

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for CHDI 00484077

	溶剂	最高浓度 mg/mL	最高浓度 mM
溶解性
	DMSO	38.24	100 温和加热
	ethanol	38.24	100 温和加热

制备储备液 for CHDI 00484077

以下数据基于产品分子量 382.39。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

浓度/溶剂体积/质量	1 mg	5 mg	10 mg
1 mM	2.62 mL	13.08 mL	26.15 mL
5 mM	0.52 mL	2.62 mL	5.23 mL
10 mM	0.26 mL	1.31 mL	2.62 mL
50 mM	0.05 mL	0.26 mL	0.52 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

产品说明书 for CHDI 00484077

分析证书/产品说明书

化学品安全技术说明书

参考文献 for CHDI 00484077

参考文献是支持产品生物活性的出版物。

Stott et al (2021) Evaluation of 5-(trifluoromethyl)-1,2,4-oxadiazole-based class IIa HDAC inhibitors for Huntington's disease. ACS Med.Chem.Lett 12 380 PMID: 33738065

If you know of a relevant reference for CHDI 00484077, please let us know.

按标靶查看相关产品

按产品操作查看相关产品

查看全部 Class II HDAC Inhibitors

关键词: CHDI 00484077, CHDI 00484077 supplier, CHDI00484077, potent, selective, inhibitors, inhibits, histone, deacetylase, class, II, IIa, HDAC4, epigenetics, Huntington, Class, HDACs, 7879, Tocris Bioscience

篇 CHDI 00484077 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 CHDI 00484077 的引用文献。您是否知道使用了 Tocris CHDI 00484077 的优秀论文？请告知我们.

CHDI 00484077 的评论

目前没有该产品的评论。 Be the first to review CHDI 00484077 and earn rewards!

Have you used CHDI 00484077?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Cell Cycle & DNA Damage Repair Poster

In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.

Epigenetics in Cancer Poster

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.